Oral contraceptive use and breast cancer: A prospective study of young women

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 10, 2010, Pages 2496-2502

  Hunter, David J ^a,b   Colditz, Graham A ^c   Hankinson, Susan E ^a,b   Malspeis, Susan ^a   Spiegelman, Donna ^a   Chen, Wendy ^b   Stampfer, Meir J ^a,b   Willett, Walter C ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETYNODIOL DIACETATE; GESTAGEN; LEVONORGESTREL; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTREL; TRIPHASIC CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; DRUG FORMULATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; UNITED STATES;

EID: 77958030647     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0747     Document Type: Article

References (27)

1. Davidson NE, Helzlsouer KJ. Good news about oral contraceptives. N Engl J Med 2002;346:2078-9.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
3. Romieu I, Willett WC, Colditz GA, et al. Prospective study of oral contraceptive use and risk of breast cancer in women. J Natl Cancer Inst 1989;81:1313-21. (Pubitemid 19221793)
4. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996;54:1-106S.
5. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-32.
6. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A case-control study of oral contraceptive use and incident breast cancer. Am J Epidemiol 2009;169:473-9.
7. Hunter DJ, Manson JE, Colditz GA, et al. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997;56:373-8.
8. Rothman KJ, Greenland S. Modern Epidemiology. 2nd edition. Philadelphia: Lippincott-Raven Publishers; 1998.
9. Romieu I, Berlin JA, Colditz GA. Oral contraceptives and breast cancer: review and meta-analysis. Cancer 1990;66:2253-63.
10. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology 1993;4:218-28.
11. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002;11:1375-81.
12. Althuis MD, Brogan DD, Coates RJ, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003;14:151-60.
13. Shantakumar S, Terry MB, Paykin A, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 2007;165:1187-98.
14. Althuis MD, Brogan DR, Coates RJ, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003;88:50-7.
15. Trivers KF, Gammon MD, Abrahamson PE, et al. Oral contraceptives and survival in breast cancer patients aged 20 to 54 years. Cancer Epidemiol Biomarkers Prev 2007;16:1822-7.
16. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000;65:659-64.
17. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91. (Pubitemid 30062864)
18. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-64.
19. Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989;20:1139-44.
20. Spicer DV, Pike MC. Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr 1994:139-47.
21. Soderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997;176:123-8.
22. Isaksson E, von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65:163-9. (Pubitemid 32193620)
23. Garcia y Narvaiza D, Navarrete MA, Falzoni R, Maier CM, Nazario AC. Effect of combined oral contraceptives on breast epithelial proliferation in young women. Breast J 2008;14:450-5.
24. Dorflinger LJ. Relative potency of progestins used in oral contraceptives. Contraception 1985;31:557-70.
25. Collins DC. Sex hormone receptor binding, progestin selectivity, and the new oral contraceptives. Am J Obstet Gynecol 1994;170:1508-13.
26. Phillips A, Hahn DW, Klimek S, McGuire JL. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1987;36:181-92.
27. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.